pharmaphorum
JANUARY 10, 2022
The arrival of COVID-19 brought precious few positives, but one that emerged for the pharmaceutical industry was the emergence and validation of mRNA vaccine technology to prevent disease. Pfizer already has a head start on competitors in the field, having achieved the first US FDA approval for an mRNA vaccine, alongside BioNTech.
Drug Discovery World
MAY 29, 2024
SpyBiotech and the University of Oxford Biotechnology company SpyBiotech and University of Oxford have entered a research agreement for the development of a vaccine against Epstein-Barr virus (EBV). We see a great need for a vaccine against EBV.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
MAY 6, 2024
As companies move through the phases of development, they benefit from a long-established ecosystem of competency in clinical regulation. So, in this way there is a cross fertilisation from the bigger companies to newer ones. More than 400 companies now make up Lithuania’s life sciences sector 4.
Pharmaceutical Technology
MAY 26, 2023
Enzymatic DNA production company Touchlight have augmented its DNA production capabilities with a newly announced expansion to its London facilities. Tripling its production capacity, Touchlight can now manufacture 8kg plasmid DNA, a key component for mRNA gene therapies and vaccines.
XTalks
DECEMBER 22, 2021
The RNA Revolution: From mRNA Vaccines to RNA Editing. RNA, and its protein-generating form messenger RNA (mRNA) discovered in 1961 , has quickly transitioned from being an obscure, finicky molecule that is difficult to work with, to becoming a significant cornerstone of therapeutic innovation in pharma and biotech.
Drug Discovery World
JANUARY 26, 2023
Research into HIV blossomed throughout 2022, with ViiV Healthcare’s combination therapy for HIV-1 gaining approval in Japan; and research moving forward towards a one-time treatment for HIV as well as a vaccine. According to research from Deloitte 1 , the average ROI in R&D for global pharma companies fell to just 1.2%
Drug Discovery World
NOVEMBER 16, 2022
On the point of consistency, the fact that organoids are a relatively new technology means that there isn’t a set ‘baseline’ in how companies grow them, with the differentiation potentially affecting research undertaken with them. “One One of the biggest pain points is really the consistency of organoids. O’Connor says.
Expert insights. Personalized for you.
108 
Let's personalize your content